Literature Collection

Collection Insights

10K+

References

9K+

Articles

1400+

Grey Literature

4500+

Opioids & SU

The Literature Collection contains over 10,000 references for published and grey literature on the integration of behavioral health and primary care. Learn More

Use the Search feature below to find references for your terms across the entire Literature Collection, or limit your searches by Authors, Keywords, or Titles and by Year, Type, or Topic. View your search results as displayed, or use the options to: Show more references per page; Sort references by Title or Date; and Refine your search criteria. Expand an individual reference to View Details. Full-text access to the literature may be available through a link to PubMed, a DOI, or a URL. References may also be exported for use in bibliographic software (e.g., EndNote, RefWorks, Zotero).

Year
Sort by
Order
Show
959 Results
121
Beyond abstinence and relapse II: momentary relationships between stress, craving, and lapse within clusters of patients with similar patterns of drug use
Type: Journal Article
Authors: L. V. Panlilio, S. W. Stull, J. W. Bertz, A. J. Burgess-Hull, S. T. Lanza, B. L. Curtis, K. A. Phillips, D. H. Epstein, K. L. Preston
Year: 2021
Abstract:

RATIONALE: Given that many patients being treated for opioid-use disorder continue to use drugs, identifying clusters of patients who share similar patterns of use might provide insight into the disorder, the processes that affect it, and ways that treatment can be personalized. OBJECTIVES AND METHODS: We applied hierarchical clustering to identify patterns of opioid and cocaine use in 309 participants being treated with methadone or buprenorphine (in a buprenorphine-naloxone formulation) for up to 16 weeks. A smartphone app was used to assess stress and craving at three random times per day over the course of the study. RESULTS: Five basic patterns of use were identified: frequent opioid use, frequent cocaine use, frequent dual use (opioids and cocaine), sporadic use, and infrequent use. These patterns were differentially associated with medication (methadone vs. buprenorphine), race, age, drug-use history, drug-related problems prior to the study, stress-coping strategies, specific triggers of use events, and levels of cue exposure, craving, and negative mood. Craving tended to increase before use in all except those who used sporadically. Craving was sharply higher during the 90 min following moderate-to-severe stress in those with frequent use, but only moderately higher in those with infrequent or sporadic use. CONCLUSIONS: People who share similar patterns of drug-use during treatment also tend to share similarities with respect to psychological processes that surround instances of use, such as stress-induced craving. Cluster analysis combined with smartphone-based experience sampling provides an effective strategy for studying how drug use is related to personal and environmental factors.

Topic(s):
Education & Workforce See topic collection
,
Opioids & Substance Use See topic collection
122
Beyond Buprenorphine: Models of Follow-up Care for Opioid Use Disorder in the Emergeny Department
Type: Journal Article
Authors: Alister Martin, Kelley Butler, Tyler Chavez, Andrew Herring, Sarah Wakeman, Bryan D. Hayes, Ali Raja
Year: 2020
Publication Place: Orange, California
Topic(s):
Education & Workforce See topic collection
,
Opioids & Substance Use See topic collection
123
Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing
Type: Journal Article
Authors: B. Andraka-Christou, A. J. Gordon, J. Spetz, R. Totaram, M. Golan, O. Randall-Kosich, J. Harrison, S. Calder, S. G. Kertesz, B. D. Stein
Year: 2022
Publication Place: United States
Topic(s):
Education & Workforce See topic collection
,
Healthcare Policy See topic collection
,
Opioids & Substance Use See topic collection
124
Bridging waitlist delays with interim buprenorphine treatment: Initial feasibility.
Type: Journal Article
Authors: Stacey C. Sigmon, Andrew C. Meyer, Bryce Hruska, Taylor Ochalek, Gail Rose, Gary J. Badger, John R. Brooklyn, Sarah H. Heil, Stephen T. Higgins, Brent A. Moore, Robert P. Schwartz
Year: 2015
Topic(s):
Opioids & Substance Use See topic collection
127
Brief vs. extended buprenorphine detoxification in a community treatment program: engagement and short-term outcomes
Type: Journal Article
Authors: E. C. Katz, R. P. Schwartz, S. King, D. A. Highfield, K. E. O'Grady, T. Billings, D. Gandhi, E. Weintraub, D. Glovinsky, W. Barksdale, B. S. Brown
Year: 2009
Publication Place: United States
Abstract: BACKGROUND: Despite evidence supporting the efficacy of buprenorphine relative to established detoxification agents such as clonidine, little research has examined: 1) how best to implement buprenorphine detoxification in outpatient settings; and 2) whether extending the length of buprenorphine detoxification improves treatment engagement and outcomes. OBJECTIVES: The current study examined the impact on 1) successful detoxification completion; 2) transition to longer-term treatment; and 3) treatment engagement of two different length opioid detoxifications using buprenorphine. METHODS: The study compared data obtained from two consecutive studies of early treatment engagement strategies. In one study (n = 364), opioid-addicted participants entered treatment through a Brief (5-day) buprenorphine detoxification. In the other study (n = 146), participants entered treatment through an Extended (i.e., 30-day) buprenorphine detoxification. RESULTS: Results indicated a greater likelihood of successful completion and of transition among participants who received the Extended as compared to the Brief detoxification. Extended detoxification participants attended more counseling sessions and submitted fewer drug-positive urine specimens during the first 30 days of treatment, inclusive of detoxification, than did Brief detoxification participants. CONCLUSIONS: Results demonstrate that longer periods of detoxification improve participant engagement in treatment and early treatment outcomes. SCIENTIFIC SIGNIFICANCE: Current findings demonstrate the feasibility of implementing an extended buprenorphine detoxification within a community-based treatment clinic.
Topic(s):
Opioids & Substance Use See topic collection
128
Buprenorphine (MOUD) Q&A
Type: Report
Authors: Drug Enforcement Administration
Year: 2023
Publication Place: Springfield, VA
Topic(s):
Healthcare Policy See topic collection
,
Opioids & Substance Use See topic collection
,
Grey Literature See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

129
Buprenorphine 101: Treating opioid dependence with buprenorphine in an office-based setting.
Type: Journal Article
Authors: Matthew Torrington, Catherine P. Domier, Maureen Hillhouse, Walter Ling
Year: 2007
Topic(s):
Opioids & Substance Use See topic collection
,
Education & Workforce See topic collection
130
Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network
Type: Journal Article
Authors: H. K. Knudsen, A. J. Abraham, J. A. Johnson, P. M. Roman
Year: 2009
Publication Place: United States
Abstract: The National Drug Abuse Treatment Clinical Trials Network (CTN), a collaborative federal research initiative that brings together universities and community-based treatment programs (CTPs), has conducted multiple clinical trials of buprenorphine for opioid dependence. Part of the CTN's mission is to promote the adoption of evidence-based treatment technologies. Drawing on a data collected during face-to-face interviews with administrators from a panel of 206 CTPs, this research examines the adoption of buprenorphine over a 2-year period. These data indicated that the adoption of buprenorphine doubled between the baseline and 24-month follow-up interviews. Involvement in a buprenorphine protocol continued to be a strong predictor of adoption at the 2-year follow-up, although adoption of buprenorphine tripled among those CTPs without buprenorphine-specific protocol experience. For-profit CTPs and those offering inpatient detoxification services were more likely to adopt buprenorphine over time. A small percentage of programs discontinued using buprenorphine. These findings point to the dynamic nature of service delivery in community-based addiction treatment and the continued need for longitudinal studies of organizational change.
Topic(s):
Opioids & Substance Use See topic collection
131
Buprenorphine and Methadone Treatment during the Perinatal Period
Type: Journal Article
Authors: Christine Savage
Year: 2008
Topic(s):
Opioids & Substance Use See topic collection
132
Buprenorphine and methadone treatment of opiate dependence during pregnancy: Comparison of fetal growth and neonatal outcomes in two consecutive case series
Type: Journal Article
Authors: Johan Kakko, Markus Heilig, Ihsan Sarman
Year: 2008
Topic(s):
Opioids & Substance Use See topic collection
133
Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic
Type: Journal Article
Authors: David Dadiomov, Maria Bolshakova, Melania Mikhaeilyan, Rebecca Trotzky-Sirr
Year: 2022
Topic(s):
Education & Workforce See topic collection
134
Buprenorphine and naloxone compared with methadone treatment in pregnancy
Type: Journal Article
Authors: S. L. Wiegand, E. M. Stringer, A. M. Stuebe, H. Jones, C. Seashore, J. Thorp
Year: 2015
Publication Place: United States
Abstract: OBJECTIVE: To compare neonatal abstinence syndrome prevalence and characteristics among neonates born to women prescribed buprenorphine and naloxone compared with methadone during pregnancy. METHODS: Retrospective cohort analysis of mother-neonate dyads treated with either buprenorphine and naloxone or methadone during pregnancy. Primary neonatal outcomes included diagnosis of neonatal abstinence syndrome, neonatal abstinence syndrome peak scores, total amount of morphine used to treat neonatal abstinence syndrome (mg), and duration of treatment for neonatal abstinence syndrome (days). Secondary outcomes included head circumference, birth weight, length, preterm birth, neonatal intensive care unit admission, Apgar scores, and overall length of hospitalization. RESULTS: From January 1, 2011, to November 30, 2013, we identified 62 mother-neonate dyads, 31 treated with methadone and 31 treated with buprenorphine and naloxone. Sixteen neonates (51.6%) in the methadone group were diagnosed with neonatal abstinence syndrome compared with eight (25.1%) in the buprenorphine and naloxone group (adjusted odds ratio 2.55, 95% confidence interval [CI] 1.31-4.98, P = .01). The buprenorphine and naloxone-exposed neonates had lower peak neonatal abstinence syndrome scores (9.0 +/- 4.4 compared with 10.7 +/- 3.7, multivariate-adjusted mean difference = -2.77, 95% CI -4.99 to -0.56, P = .02) and shorter overall hospitalization (5.6 +/- 5.0 compared with 9.8 +/- 7.4 days, multivariate-adjusted mean difference = -3.90, 95% CI, -7.13 to -0.67, P = .02). We found no other differences in primary or secondary outcomes. CONCLUSION: In a cohort of pregnant patients treated with either methadone or buprenorphine and naloxone in pregnancy, newborns exposed to maternal buprenorphine and naloxone had less frequent neonatal abstinence syndrome. Additionally, neonates exposed to buprenorphine and naloxone had shorter overall hospitalization lengths.
Topic(s):
Opioids & Substance Use See topic collection
,
Healthcare Disparities See topic collection
135
Buprenorphine and Naloxone Versus Buprenorphine for Opioid Use Disorder in Pregnancy: A Cohort Study
Type: Journal Article
Authors: Nathan Mullins, Shelley L. Galvin, Melinda Ramage, Marie Gannon, Kathleen Lorenz, Brent Sager, Carol C. Coulson
Year: 2020
Publication Place: Baltimore, Maryland
Topic(s):
Education & Workforce See topic collection
,
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
136
Buprenorphine deregulation as an opioid crisis policy response - A comparative analysis between France and the United States
Type: Journal Article
Authors: A. Sud, K. Chiu, J. Friedman, J. Dupouy
Year: 2023
Topic(s):
Opioids & Substance Use See topic collection
,
Healthcare Policy See topic collection
137
Buprenorphine dispensing among youth aged ≤19 years in the United States: 2015–2020
Type: Journal Article
Authors: Andrew Terranella, Gery P. Guy Jr., Christina Mikosz
Year: 2023
Topic(s):
Healthcare Disparities See topic collection
138
Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky
Type: Journal Article
Authors: Hannah L. F. ScD. Cooper, David H J.D. M.P.H. Cloud, Patricia R RPh F.A.PhA. F.N.A.P. Freeman PhD, Monica B.S. Fadanelli, Travis B.S.W. Green, Connor BS Van Meter, Stephanie Beane PhD., Umedjon Ibragimov PhD., April M. Young PhD.
Year: 2020
Publication Place: Amsterdam
Topic(s):
Education & Workforce See topic collection
,
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
139
Buprenorphine Dosage and Urine Quantitative Buprenorphine, Norbuprenorphine, and Creatinine Levels in an Office-Based Opioid Treatment Program
Type: Journal Article
Authors: Hiroko Furo, Diane G. Schwartz, Ross W. Sullivan, Peter L. Elkin
Year: 2021
Publication Place: Thousand Oaks, California
Topic(s):
Education & Workforce See topic collection
,
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
140
Buprenorphine dosing choices in specific populations: review of expert opinion
Type: Journal Article
Authors: I. Maremmani, B. Rolland, L. Somaini, C. Roncero, J. Reimer, N. Wright, R. Littlewood, P. Krajci, H. Alho, O. D'Agnone, N. Simon
Year: 2016
Abstract: Introduction Treatment of opioid dependence with buprenorphine improves outcomes. Typical dosing ranges for all patients from clinical evidence and as defined in the product information are wide. For specific groups with complex clinical scenarios, there is no clear consensus on dosing choices to achieve best possible outcomes. Areas covered The doses of buprenorphine used in 6 European countries was reviewed. A review of published evidence supported rapid induction with buprenorphine and the benefits of higher doses but did not identify clearly useful guidance on dosing choices for groups with complex clinical scenarios. An expert group of physicians with experience in addiction care participated in a discussion meeting to share clinical practice experience and develop a consensus on dosing choices. Expert opinion There was general agreement that treatment outcomes can be improved by optimising buprenorphine doses in specific subgroups. Specific groups in whom buprenorphine doses may be too low and who could have better outcomes with optimised dosing were identified on the basis of clinical practice experience. These groups include people with severe addiction, high tolerance to opioids, and psychiatric comorbidities. In these groups it is recommended to review dosing choices to ensure buprenorphine dosing is sufficient.
Topic(s):
Opioids & Substance Use See topic collection